TY - JOUR
T1 - Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria
AU - Buters, Thomas P.
AU - van der Velden, Willemijn W.A.C.
AU - Abdisalaam, Ismahaan
AU - van Maaren, Maurits S.
AU - van Doorn, Martijn B.A.
N1 - Funding Information:
Conflicts of interest: Dr van Doorn reports personal fees from Leopharma, grants and personal fees from Novartis, personal fees from Abbvie, personal fees from BMS, personal fees from Celgene, personal fees from Lilly, personal fees from MSD, personal fees from Pfizer, personal fees from Sanofi-Genzyme, and personal fees from Janssen Cilag, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
PY - 2021/8
Y1 - 2021/8
UR - http://www.scopus.com/inward/record.url?scp=85105531713&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.04.034
DO - 10.1016/j.jaip.2021.04.034
M3 - Article
C2 - 33915307
AN - SCOPUS:85105531713
VL - 9
SP - 3227
EP - 3229
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 8
ER -